Sanofi: Influenza, Human trials

The registry lists 139 Influenza, Human studies with Sanofi as lead sponsor. 4 are open to participants now and 73 have results posted.

Phase 1 24Phase 2 47Phase 3 35Phase 4 33No phase 13(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult SubjectsCompletedNCT04451954Phase 1
• Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of AgeCompletedNCT04210349Phase 3
• Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of AgeCompletedNCT04144179Phase 1
• Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in VietnamCompletedNCT03765437Phase 3
• Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza VaccineCompletedNCT03430089Phase 1
• Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza VaccineCompletedNCT03391193Phase 3
• Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 YearsCompletedNCT03344029Phase 4
• Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy RegistryCompletedNCT02554409
• A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and OlderCompletedNCT02553343Phase 2
• Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy RegistryCompletedNCT01945424
• Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and AdultsCompletedNCT01481454Phase 3
• Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in KoreaCompletedNCT01215669Phase 4
• Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intradermal Route)CompletedNCT01138397Phase 3
• Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 Northern Hemisphere Season, Intramuscular Route)CompletedNCT01121822Phase 3
• A Study of the Immunogenicity of Swine-origin A/H1N1 Influenza Vaccine in Healthy AdultsCompletedNCT01089660Phase 2
• Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in IndiaCompletedNCT01053143Phase 3
• Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and AdultsCompletedNCT01032980
• A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 YearsCompletedNCT00956202Phase 2
• A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 MonthsCompletedNCT00956046Phase 2
• A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy European Adults and the ElderlyCompletedNCT00954798Phase 2
• Study of Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 FormulationCompletedNCT00946179Phase 2
• Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route)CompletedNCT00945438Phase 2
• Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in ChildrenCompletedNCT00884182Phase 2
• Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza VaccinesCompletedNCT00776438Phase 2
• Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 FormulationCompletedNCT00718146Phase 2
• Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in AdultsCompletedNCT00703651Phase 2
• Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted VaccineCompletedNCT00664417Phase 1
• Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant SubjectsCompletedNCT00606359Phase 2
• Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM VaccineCompletedNCT00554333Phase 3
• Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in AdultsCompletedNCT00545701Phase 2
• Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in ChildrenCompletedNCT00491985Phase 2
• A Study of the Immunogenicity and Safety of the 2007-2008 Influenza VaccineCompletedNCT00491257Phase 2
• Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the ElderlyCompletedNCT00415129Phase 2
• Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in AdultsCompletedNCT00383539Phase 3
• Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the ElderlyCompletedNCT00383526Phase 3
• A Study of the Immunogenicity and Safety of the 2006-2007 Influenza VaccineCompletedNCT00343681Phase 2
• Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the ElderlyCompletedNCT00296829Phase 2
• Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
• Immunogenicity Study of the Influenza Vaccine in AdultsCompletedNCT00258934Phase 2